HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ: FDMT) and maintained a price target of $36 for the stock.